Market Overview

UPDATE: Stifel Nicolaus Downgrades Medicis Pharmaceutical to Hold

Related MRX
Valeant Pharmaceuticals And Galderma Agree On Revised Agreement Terms
Medicis Pharmaceutical Spikes Higher on 8-K Filing Regarding Dismissed Lawsuit

Stifel Nicolaus reduced its rating on Medicis Pharmaceutical (NYSE: MRX) from Buy to Hold and suspends its price target, previously at $42 a share.

Stifel Nicolaus noted, "In light of Valeant's $44/share takeout bid for Medicis and subsequent stock runup, we currently view Medicis shares as trading at fair value. Due to the highly complementary portfolios and cost synergies from a VRX-MRX combination, along with significant accretion potential by applying VRX's tax structure to MRX's assets, we do not expect a considerably higher competitive bid in coming months (though possible). Furthermore, the fact that both companies' boards agreed to the deal indicates to us that the negotiation was friendly and price was mutually acceptable. Any incremental bids, in our view, would be only modestly higher."

Medicis Pharmaceutical closed at $43.65 on Tuesday.

Latest Ratings for MRX

DateFirmActionFromTo
Oct 2012Morgan StanleyMaintainsEqual-weight
Sep 2012DowngradesPositiveNeutral
Sep 2012SusquehannaDowngradesPositiveNeutral

View More Analyst Ratings for MRX
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Downgrades Intraday Update Analyst Ratings

 

Related Articles (MRX + VRX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters